The discovery by Honjo et al. that the binding of PD-1/PD-L1 induces T-cell exhaustion inspired the idea of inhibiting this mechanism as a new strategy in cancer immunotherapy, which was worth further investigation [22]. Here, PDCD1 is linked to cancer.